High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1543-1556

  He, Shihan ^a   Senter, Timothy J ^b,c,d   Pollock, Jonathan ^a   Han, Changho ^b,c   Upadhyay, Sunil Kumar ^a   Purohit, Trupta ^a   Gogliotti, Rocco D ^b,c   Lindsley, Craig W ^b,c,d   Cierpicki, Tomasz ^a   Stauffer, Shaun R ^b,c,d   Grembecka, Jolanta ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 (CYCLOPENTYLAMINOPHENYLMETHYL)PIPERIDIN 1 YL]PROPOXY]BENZONITRILE; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR SCAFFOLD; PIPERIDINE DERIVATIVE; PROTEIN; PROTEIN INHIBITOR; PROTEIN MENIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LEUKEMIA CELL; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION;

CALORIMETRY; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PIPERIDINES; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84896871890     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401868d     Document Type: Article

References (40)

1. Kar, G.; Gursoy, A.; Keskin, O. Human cancer protein-protein interaction network: a structural perspective PLoS Comput. Biol. 2009, 5, e1000601
2. Fry, D. C. Protein-protein interactions as targets for small molecule drug discovery Biopolymers 2006, 84, 535-552
3. Buchwald, P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations IUBMB Life 2010, 62, 724-731
4. Azzarito, V.; Long, K.; Murphy, N. S.; Wilson, A. J. Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules Nature Chem. 2013, 5, 161-173
5. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009
6. Morelli, X.; Bourgeas, R.; Roche, P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I) Curr. Opin. Chem. Biol. 2011, 15, 475-481
7. Arkin, M. R.; Whitty, A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions Curr. Opin. Chem. Biol. 2009, 13, 284-290
8. Smith, M. C.; Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity Expert Rev. Mol. Med. 2012, 14, e16
9. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
10. Ray-Coquard, I.; Blay, J. Y.; Italiano, A.; Le Cesne, A.; Penel, N.; Zhi, J.; Heil, F.; Rueger, R.; Graves, B.; Ding, M.; Geho, D.; Middleton, S. A.; Vassilev, L. T.; Nichols, G. L.; Bui, B. N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Lancet Oncol. 2012, 13, 1133-1140
11. Yokoyama, A.; Somervaille, T. C.; Smith, K. S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M. L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis Cell 2005, 123, 207-218
12. Slany, R. K. When epigenetics kills: MLL fusion proteins in leukemia Hematol. Oncol. 2005, 23, 1-9
13. Marschalek, R. Mechanisms of leukemogenesis by MLL fusion proteins Br. J. Hamaetol. 2011, 152, 141-154
14. Tomizawa, D.; Koh, K.; Sato, T.; Kinukawa, N.; Morimoto, A.; Isoyama, K.; Kosaka, Y.; Oda, T.; Oda, M.; Hayashi, Y.; Eguchi, M.; Horibe, K.; Nakahata, T.; Mizutani, S.; Ishii, E. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group Leukemia 2007, 21, 2258-2263
15. Popovic, R.; Zeleznik-Le, N. J. MLL: how complex does it get? J. Cell Biochem. 2005, 95, 234-242
16. Dimartino, J. F.; Cleary, M. L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies Br. J. Hamaetol. 1999, 106, 614-626
17. Hess, J. L. MLL: a histone methyltransferase disrupted in leukemia Trends Mol. Med. 2004, 10, 500-507
18. Krivtsov, A. V.; Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development Nature Rev. Cancer 2007, 7, 823-833
19. Slany, R. K. The molecular biology of mixed lineage leukemia Haematologica 2009, 94, 984-993
20. Grembecka, J.; Belcher, A. M.; Hartley, T.; Cierpicki, T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias J. Biol. Chem. 2010, 285, 40690-40698
21. Caslini, C.; Yang, Z.; El-Osta, M.; Milne, T. A.; Slany, R. K.; Hess, J. L. Interaction of MLL amino terminal sequences with menin is required for transformation Cancer Res. 2007, 67, 7275-7283
22. Yokoyama, A.; Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes Cancer Cell 2008, 14, 36-46
23. Shi, A.; Murai, M. J.; He, S.; Lund, G.; Hartley, T.; Purohit, T.; Reddy, G.; Chruszcz, M.; Grembecka, J.; Cierpicki, T. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia Blood 2012, 120, 4461-4469
24. Murai, M. J.; Chruszcz, M.; Reddy, G.; Grembecka, J.; Cierpicki, T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein J. Biol. Chem. 2011, 286, 31742-31748
25. Grembecka, J.; He, S.; Shi, A.; Purohit, T.; Muntean, A. G.; Sorenson, R. J.; Showalter, H. D.; Murai, M. J.; Belcher, A. M.; Hartley, T.; Hess, J. L.; Cierpicki, T. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia Nature Chem. Biol. 2012, 8, 277-284
26. Zhou, H.; Liu, L.; Huang, J.; Bernard, D.; Karatas, H.; Navarro, A.; Lei, M.; Wang, S. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction J. Med. Chem. 2013, 56, 1113-1123
27. Manka, J.; Daniels, R. N.; Dawson, E.; Daniels, J. S.; Southall, N.; Jadhav, A.; Zheng, W.; Austin, C.; Grembecka, J.; Cierpicki, T.; Lindsley, C. W.; Stauffer, S. R. In Probe Reports from the NIH Molecular Libraries Program; National Institutes of Health: Bethesda, MD, 2013.
28. Cowan, D. O.; Mosher, H. S. Comparison of the Reactions of Grignard Reagents and Dialkylmagnesium Compounds in Addition, Reduction, and Enolization Reactions J. Org. Chem. 1962, 27, 1-5
29. Honkanen, E.; Pippuri, A.; Kairisalo, P.; Nore, P.; Karppanen, H.; Paakkari, I. Synthesis and antihypertensive activity of some new quinazoline derivatives J. Med. Chem. 1983, 26, 1433-1438
30. Chen, Y. X.; Yan, J.; Keeshan, K.; Tubbs, A. T.; Wang, H.; Silva, A.; Brown, E. J.; Hess, J. L.; Pear, W. S.; Hua, X. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1018-1023
31. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
32. Mayer, M.; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor J. Am. Chem. Soc. 2001, 123, 6108-6117
33. Otwinowski, Z.; Minor, W. In Macromolecular Crystallography, Part A; Methods in Enzymology; Academic Press: New York, 1997; Vol. 276, pp 307-326
34. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
35. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr 2004, 60, 2126-2132
36. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
37. Painter, J.; Merritt, E. A. TLSMD web server for the generation of multi-group TLS models J. Appl. Crystallogr. 2006, 39, 109-111
38. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., III; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 2007, 35, W375-383
39. Yang, H.; Guranovic, V.; Dutta, S.; Feng, Z.; Berman, H. M.; Westbrook, J. D. Automated and accurate deposition of structures solved by X-ray diffraction to the Protein Data Bank Acta Crystallogr., Sect. D: Biol.Crystallogr. 2004, 60, 1833-1839
40. Muntean, A. G.; Tan, J.; Sitwala, K.; Huang, Y.; Bronstein, J.; Connelly, J. A.; Basrur, V.; Elenitoba-Johnson, K. S.; Hess, J. L. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis Cancer Cell 2010, 17, 609-621